TScan Therapeutics, Inc. - TCRX STOCK NEWS

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company, will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on March 8, 2023, at 2:10 p.m. ET in Boston, MA. The panel will focus on the development of T cell receptor (TCR)-engineered therapies for cancer treatment. A live webcast can be accessed through the Company’s website, with an archived replay available for 30 days post-event. TScan's lead candidates, TSC-100 and TSC-101, target hematologic malignancies while expanding their ImmunoBank for solid tumor therapies.

TScan Therapeutics (Nasdaq: TCRX), a biopharmaceutical company specializing in T cell receptor (TCR)-engineered T cell therapies, announced its participation in the H.C. Wainwright Cell Therapy Virtual Conference on February 28, 2023, at 3:30 p.m. Eastern Time. The presentation will be accessible via webcast on the Company’s website. TScan is developing lead therapy candidates TSC-100 and TSC-101 for treating hematologic malignancies, aiming to eliminate residual disease post-transplantation. Additionally, the company is building its ImmunoBank to provide customized therapies targeting various solid tumors.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the FDA's clearance of its investigational new drug (IND) applications for its solid tumor program, T-Plex, along with two TCR-T products targeting MAGE-A1. T-Plex will facilitate customized combinations of TCR-T therapies, enabling personalized treatment based on tumor characteristics. The first two INDs target specific HLA types and are pivotal for advancing TScan's ImmunoBank. The company plans to initiate a multicenter Phase 1 clinical trial for various cancers by mid-2023, with initial results expected by year-end, marking significant progress in tailored cancer therapies.

TScan Therapeutics (TCRX) announced progress in its clinical pipeline, focusing on T cell receptor (TCR)-engineered therapies for cancer. The Phase 1 umbrella trial for treatments TSC-100 and TSC-101 is active across five sites, with expectations to enroll first cohorts in 1H 2023 and interim data due by year-end. The company has filed INDs for multiple TCRs targeting solid tumors and has sufficient cash to fund operations into Q2 2024. Leadership emphasized 2023 as a pivotal year, anticipating significant data readouts.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced the presentation of its Phase 1 trial design for TSC-100 and TSC-101, aimed at treating residual leukemia post-hematopoietic cell transplantation (HCT), at the 64th American Society of Hematology Annual Meeting 2022. The therapies target specific minor histocompatibility antigens and aim to reduce disease relapse. The company plans to enroll the first trial cohorts in H1 2023, with interim data expected by the end of 2023.

TScan Therapeutics, Inc. (Nasdaq: TCRX) announced participation in the 5th Annual Evercore ISI HealthCONx Conference on November 29, 2022, at 10:55 a.m. ET. The management will engage in a virtual fireside chat, which will be available via webcast on the company's website under the "Events and Presentations" section. An archived replay will be accessible for 90 days post-event. TScan is focused on developing T cell receptor-engineered therapies for cancer, targeting residual disease and relapse prevention in patients with hematologic malignancies.

TScan Therapeutics (TCRX) is advancing its T cell receptor-engineered therapies for cancer treatment, focusing on multiplexed TCR-T therapy against solid tumors. The company presented key findings at the SITC Annual Meeting, highlighting the discovery of PRAME-specific TCRs showing strong in vitro and in vivo efficacy. TScan plans to file IND applications for two candidates by the end of 2022 and aims to expand its ImmunoBank for customized therapies. These developments indicate a commitment to addressing tumor heterogeneity and improving treatment outcomes.

TScan Therapeutics (TCRX) announced strong progress in its hematologic malignancies program, with four sites now enrolling patients. The company completed a pre-IND meeting with the FDA for its solid tumor program, indicating a clear path for future IND filings. TScan ended Q3 2022 with $137.3 million in cash, projected to fund operations through Q2 2024. Revenue surged to $3.4 million, up from $2.4 million year-over-year, driven by a collaboration with Novartis. However, TScan reported a net loss of $16.2 million, slightly higher than the previous year.